A new study conducted by the Sleep Centre at the University of Pennsylvania School of Medicine finds that there is a new treatment for people who suffer from moderate to severe obstructive sleep apnea (OSA) and are unable to tolerate standard therapy. This implantable, nerve-stimulating device has successfully eased symptoms of the condition. In the USA 18 million adults are affected by OSA, with men at greater risk than women. OSA is a condition that occurs when the muscles at the back of the throat collapses and closes during sleep, blocking airflow. This can cause brief and repeated pauses in breathing that last for at least 10 seconds. OSA can result in sleep disruptions and low blood oxygen levels. This increases the risk of memory and mood problems, high blood pressure and heart disease.